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Abstract
IMPORTANCE There is no proven test that can guide the optimal treatment, either endocrine
therapy or chemotherapy, for estrogen receptor–positive breast cancer.
OBJECTIVE To investigate the associations of sperm-associated antigen 5 (SPAG5) transcript and
SPAG5 protein expressions with treatment response in systemic therapy for estrogen receptor–
positive breast cancer.
DESIGN, SETTINGS, AND PARTICIPANTS This retrospective cohort study included patients with
estrogen receptor–positive breast cancer who received 5 years of adjuvant endocrine therapywith or
without neoadjuvant anthracycline-based combination chemotherapy (NACT) derived from 11
cohorts from December 1, 1986, to November 28, 2019. The associations of SPAG5 transcript and
SPAG5 protein expression with pathological complete response to NACTwere evaluated, as was the
association of SPAG5 mRNA expression with response to neoadjuvant endocrine therapy. The
associations of distal relapse–free survival with SPAG5 transcript or SPAG5 protein expressions were
analyzed. Data were analyzed from September 9, 2015, to November 28, 2019.
MAIN OUTCOMES ANDMEASURES The primary outcomes were breast cancer–specific survival,
distal relapse–free survival, pathological complete response, and clinical response. Outcomes were
examined using Kaplan-Meier, multivariable logistic, and Cox regressionmodels.
RESULTS This study included 12 720women aged 24 to 78 years (mean [SD] age, 58.46 [12.45]
years) with estrogen receptor–positive breast cancer, including 1073 womenwith SPAG5 transcript
expression and 361 women with SPAG5 protein expression of locally advanced disease stage IIA
through IIIC. Womenwith SPAG5 transcript and SPAG5 protein expressions achieved higher
pathological complete response compared with those without SPAG5 transcript or SPAG5 protein
expressions (transcript: odds ratio, 2.45 [95% CI, 1.71-3.51]; P < .001; protein: odds ratio, 7.32 [95%
CI, 3.33-16.22]; P < .001). Adding adjuvant anthracycline chemotherapy to adjuvant endocrine
therapy for SPAG5 mRNA expression in estrogen receptor–positive breast cancer was associated with
prolonged 5-year distal relapse–free survival in patients without lymph node involvement (hazard
ratio, 0.34 [95% CI, 0.14-0.87]; P = .03) and patients with lymph node involvement (hazard ratio,
0.35 [95% CI, 0.18-0.68]; P = .002) compared with receiving 5-year endocrine therapy alone. Mean
(SD) SPAG5 transcript was found to be downregulated after 2 weeks of neoadjuvant endocrine
therapy compared with pretreatment levels in 68 of 92 patients (74%) (0.23 [0.18] vs 0.34 [0.24];
P < .001).
(continued)
Key Points
Question Are sperm-associated
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE These findings suggest that SPAG5 transcript and SPAG5 protein
expressions could be used to guide the optimal therapies for estrogen receptor–positive breast
cancer. Retrospective and prospective clinical trials are warranted.
JAMA Network Open. 2020;3(7):e209486. doi:10.1001/jamanetworkopen.2020.9486
Introduction
Among 1.38million newly diagnosed breast cancer cases each year, 65% to 70% of them are
estrogen receptor positive.1 Although single-agent endocrine therapy has significantly extended
survival for patients with estrogen receptor–positive breast cancer, resistance to endocrine therapy
is common, reported in up to 50% of patients.2 To extend treatment benefit and delay the
development of endocrine therapy resistance, a combination of endocrine therapy with cytotoxic
chemotherapy has been proven to be effective in up to 30% of estrogen receptor–positive
breast cancers.3-6
Currently, there is no proven test that can accurately predict response to endocrine therapy or
chemotherapy. The current practice is largely based on assessment of the recurrence risk and overall
survival (OS), using traditional clinicopathological prognostic factors (eg, lymph node status) and
multigene tests (eg, Oncotype DX [Genomic Health], MammaPrint [Agendia], and Prosigna
[Nanostring Technologies]).7 However, these tests are used to assess outcomes and do not predict if
a patient will respond to endocrine therapy or chemotherapy; therefore, it can be difficult for
clinicians and patients to determine the risk/benefit ratio associated with endocrine therapy or
chemotherapy or to select the effective treatment for individual patients. Therefore, there is a need
for an improved method of determining if an individual is likely to respond to chemotherapy or
endocrine therapy.
Previously, we reported that sperm-associated antigen 5 (SPAG5; OMIM 615562) is a novel
oncogene in estrogen receptor–positive luminal-B subtype breast cancer.8,9 The aim of this study was
to analyze the association of SPAG5 gene and SPAG5 protein expression in estrogen receptor–positive
breast cancer with treatment response, whichmay enable better management of estrogen
receptor–positive breast cancer.
Methods
StudyDesign and Cohorts
This study was approved by the institutional review board, independent ethics committee, or
hospital research and innovations department at all participating sites. Oral and written consent was
obtained from participants prior to the investigation. The participants did not receive financial
compensation. This study followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline for cohort studies. The study design and patient cohorts
are summarized in Figure 1.
Patient Cohorts
The study was conducted in 11 cohorts of womenwith estrogen receptor–positive breast cancer from
December 1, 1986, to November 28, 2019 (eAppendix in the Supplement): theMolecular Taxonomy
of Breast Cancer International Consortium (METABRIC) cohort10,11; The Cancer Genome Atlas-Breast
Cancer project (TCGA-BRCA) cohort12; the Swegene cohort13; the multicenter Gene Expression
databases (MC-GEDBs) cohort, which was derived from publishedmicroarray data sets as previously
described14; the NottinghamUniversity Hospital early stage breast cancers (NUH-ESBC) cohort; the
estrogen receptor–positive Queensland breast cancer follow-up (QBCFU) cohort; the neoadjuvant
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endocrine therapy (NET) cohort, which included patients who received aromatase inhibitors andwas
derived from 3 publishedmicroarray data sets (ie, GSE59515, GSE55374 andGSE20181) as previously
described15; the multicenter neoadjuvant anthracycline combination chemotherapy (MC-NACT)
cohort, which was derived from 11 databases; the NUH locally advanced breast cancer (NUH-LABC)
cohort; the MD Anderson Cancer Center (MDACC) cohort,16 which included patients with recently
diagnosed estrogen receptor–positive breast cancer who did not have HER2 (OMIM 164870) gene
expression and whowere treated with NACTwith taxane followed by 5-year adjuvant endocrine
therapy16; and themulticenter adjuvant therapy (MC-AT) cohort, which was retrieved from 17
multicenter databases of patients with estrogen receptor–positive early stage breast cancer who had
received systemic adjuvant therapy.
Measurement and Procedures
SPAG5 CopyNumber Variants
Copy number variants at the SPAG5 locus on chromosome 17q11.2 were retrieved from the
METABRIC,10,11 TCGA-BRCA,12 and Swegene consortium13 cohorts. For the Swegene cohort, bacterial
artificial chromosomemicroarrayswere produced by the SCIBLUGenomics Centre, LundUniversity,
Lund, Sweden.13 For the METABRIC and TCGA-BRCA cohorts, breast cancers were assayed using
Affymetrix 6.0 SNP arrays, and the whole exome sequencing data were obtained for the TCGA-BRCA
cohort.12 The aligned TCGA-BRCA data sets were downloaded using the CGHub download client
software GeneTorrent version 3.8.5 as previously described.14
SPAG5 Surrogate Transcriptomic Signature
The SPAG5 surrogate transcriptomic signature, which corresponded to each type of SPAG5 variant
and included upregulated and downregulated genes, was identified using SPAG5 genotype. Data on
Figure 1. Cohort FlowDiagram
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aCGH indicates array comparative genomic hybridization; AT, adjuvant therapy; IHC,
immunohistochemistry; MC-GEDB, multicenter Gene Expression databases; MC-NACT,
multicenter neoadjuvant anthracycline combination chemotherapy; MDACC, MD
Anderson Cancer Center; METABRIC indicates Molecular Taxonomy of Breast Cancer
International Consortium; NACT, neoadjuvant anthracycline-based combination
chemotherapy; NET, neoadjuvant endocrine therapy; NGS, next generation sequencing;
NUH-ESBC, NottinghamUniversity Hospital early stage breast cancer; NUH-LABC,
NottinghamUniversity Hospital locally advanced breast cancer; QBCFU, Queensland
breast cancer follow-up; SPAG5, sperm-associated antigen 5; and TCGA-BRCA, The
Cancer Genome Atlas-Breast Cancer project.
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RNA sequence were derived from next generation sequencing in the TCGA-BRCA cohort, as
previously described.14
SPAG5Gene Expression
Expression of SPAG5 in mRNAwas determined in publicly available gene expression data, including
the METABRIC, TCGA-BRCA, Swegene, NET, MC-NACT, MDACC, and MC-AT cohorts. The gene
expression raw data were downloaded using the raw data format as described previously.8,14
SPAG5 Protein Expression
Immunohistochemistry (IHC) of SPAG5 protein expression and other breast cancer biomarkers were
investigated in the NUH-LABC, NUH-ESBR, andQBCFU cohorts (eTable 1 in the Supplement).5 SPAG5
protein expression was also evaluated in post-NACT surgical specimens from patients who had not
achieved pathological complete response (CR) in the NUH-LABC cohort. Immunohistochemistry was
performed using an anti-SPAG5 antibody (HPA022479; Sigma) at a dilution of 1:50.
OutcomeMeasurements
Molecular characteristic associations of SPAG5 expression (ie, copy number variants andmRNA) were
determined in theMETABRIC, TCGA-BRCA, and Swegene cohorts. The clinicopathological
associations of SPAG5 protein expression were evaluated in the NUH-ESBC and QBCFU cohorts.
Survival
We defined OS as the number of months from diagnosis to the occurrence of death. Survival was
censored if the patient was still alive or lost to follow-up by November 28, 2019. The association of
SPAG5 variant transcriptomic signature with OS was analyzed in theMC-GEDBs cohort, as previously
described.14
Breast cancer–specific survival (BCSS) was defined as the number of months from diagnosis to
the occurrence of death caused by breast cancer. The association of the SPAG5 protein expression
with BCSS was analyzed in theMETABRIC, Swegene, NUH-ESBC, and QBCFU cohorts.
Distant relapse free survival (DRFS) was defined as the number of months from diagnosis to
distant metastases relapse. The association of prechemotherapy SPAG5 mRNA expression with DRFS
was evaluated in theMDACC cohort. The association of DRFS with SPAG5 mRNA expression was
tested in theMC-AT cohort, and the association of SPAG5 protein expression was tested in the
NUH-ESBC cohort. The associations of DRFS with SPAG5 protein expressions in pre- and post-NACT
tissue samples were analyzed in NUH-LABC cohort.
Treatment Response
Serial dynamic clinical response to neoadjuvant endocrine therapywas determined in the NET cohort
bymeasuring tumor volumes during a 3-month treatment period and verified bymammographic
measurements. Nonresponse was defined by an increase in tumor volume or a partial reduction that
never exceeded 50%.15 The associations of SPAG5 mRNA expression before (after 2 weeks) and
during (after 3 months) treatment with clinical response were evaluated.
Pathological CR rate was defined as absence of any neoplastic cells in the primary breast site
and lymph nodes after receiving NACT. The association of SPAG5 mRNA expression with pathological
CR was evaluated in theMC-NACT cohort. The associations of SPAG5 protein expression in the
pre-NACT diagnostic core biopsies with pathological CR after receiving NACTwere investigated in
the NUH-LABC cohort.
Statistical Analysis
Statistical analyses were performed using Statistica (Stat Soft ) and SPSS version 17 (IBM). Where
appropriate, Pearson χ2, t test, and analysis of variance tests were used. Expression of SPAG5 protein
before and after chemotherapy was calculated and compared using McNemar test. Cumulative
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survival probabilities, 10-year OS, and 5-year DRFS were estimated using the univariate Cox
proportional hazards models and the Kaplan-Meier plot method where appropriate, and differences
between survival rateswere tested for significance using the log-rank test. Multivariable analysis for
survival was performed using the Cox proportional hazard model. The proportional hazards
assumptionwas tested using standard log-log plots. Hazard ratios (HRs) and 95%CIs were estimated
for each variable. All tests were 2-sided, and P < .05 was considered statistically significant. The
associations of SPAG5 transcript and SPAG5 protein expressions with chemotherapy were tested
using Cox proportional hazardmodel. For multiple comparisons, P values were adjusted according to
Benjamini-Hochberg method. Data were analyzed from September 9, 2015, to November 28, 2019.
Results
This study included 12 720women aged 24 to 78 years (mean [SD] age, 58.46 [12.45] years) with
estrogen receptor–positive breast cancer derived from 11 cohorts. TheMETABRIC cohort10,11 included
1498 patients with median (interquartile range [IQR]) follow-up time of 9.1 (5.2-12.9) years (eTable 2
in the Supplement). The TCGA-BRCA cohort12 included 381 patients with a median (IQR) follow-up
time of 1.9 (1.7-3.6) years (eTable 3 in the Supplement). The Swegene cohort13 included 227 patients
with a median (IQR) follow-up time of 8.1 (5.0-14.0) years (eTable 4 in the Supplement). The
MC-GEDBs cohort14 included 3144 patients. There were 2500 patients in the NUH-ESBC cohort,
including 1175 patients (47%) whowere adjuvant therapy–naive, 1050 patients (42%) who received
5-year adjuvant endocrine therapy alone, and 275 patients (11%) who received adjuvant endocrine
therapy and chemotherapy. Among 2105 patients in the NUH-ESBC cohort with HER2 gene
expression (7%), none received trastuzumab (eTable 5 in the Supplement). Median (IQR) follow-up
time in the NUH-ESBC cohort was 13.4 (10.3-16.4) years. The QBCFU cohort included 287 patients.
There were 101 patients in the NET cohort15 (eTable 6 in the Supplement). The MC-NACT cohort
included 1073 patients, among whom 754 (70%) received NACTwith taxane, 268 (25%) received
NACT alone, and 51 (5%) received NACTwith taxane and trastuzumab (eTable 7 and eTable 8 in the
Supplement). The NUH-LABC cohort included 361 patients with a median (IQR) follow-up time of 5.1
(3.4-7.0) years, among whom 207 (58%) received NACT with taxane, 104 (29%) received NACT
alone, and 45 (13%) received NACTwith taxane and trastuzumab. Additionally, 25 patients (7%) did
not receive adjuvant therapy, 180 patients (51%) received adjuvant endocrine therapy alone, and 151
patients (42%) received adjuvant endocrine therapywith chemotherapy. A total of 103 patients with
HER2 expression (29%) received adjuvant trastuzumab (eTable 9 in the Supplement). The MDACC
cohort included 299 patients, andmedian (IQR) follow-up time was 9.0 (5.7-10.5) years (eTable 10 in
the Supplement). TheMC-AT cohort included 2521 patients withmedian (IQR) follow-up time of 5.4
(3.0-8.7) years (eTable 11 and eTable 12 in the Supplement). Among patients in the MC-AT cohort,
1408 patients (75%) received adjuvant endocrine therapy alone, including 1376 patients (75%) who
received tamoxifen and 32 patients (2%)who received aromatase inhibitors, whereas 394 patients
(28%) received chemotherapy in addition to adjuvant endocrine therapy; 253 patients (18%)
received anthracycline with taxane, 85 patients (6%) received anthracycline alone, and 56 patients
(4%) received cyclophosphamide, methotrexate, and fluorouracil. Among 282 patients with HER2
expression (20%), only 11 patients (4%) received adjuvant trastuzumab.
Gain-amplification of SPAG5 gene locus at chromosome 17q11.2 was more common in PAM50
luminal-B vs luminal-A (TCGA-BRCA: 72 of 230 patients [31%] vs 65 of 479 patients [14%]; P < .001;
METABRIC: 87 of 488 patients [18%] vs 45 of 718 patients [6%]; P < .001; Swegene: 10 of 64
patients [16%] vs 1 of 89 patients [1%]; P < .001). Expression of SPAG5 in mRNAwas associated with
luminal-B (determined via PAM50 and 4-IHC), TP53 (OMIM 191170) variation, HER2 expression, BRCA2
(OMIM600185) variation, luminal-complex genomic pattern, 17q12 genomic patterns, and high genomic
instability integrative clusters (IntClust 1, 2 5, 6, 9 and 10) in theMETABRIC and Swegene cohorts
(eTable 13 and eTable 14 in the Supplement). In contrast, no SPAG5 expression was associated with
luminal-A, paucity of genomic changes, luminal-simplex genomic pattern (1q positive and 16q negative),
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low genomic instability, and IntClust 3, 4, and 8 (METABRIC and Swegene cohorts) (eTable 13 and
eTable 14 in the Supplement). Expression of SPAG5 in protein was associated with luminal-B (4-IHC),
HER2 expression, and TP53 variation (eTable 15 in the Supplement).
Expressions of SPAG5 in copy number variant gain-amplification andmRNA and SPAG5 protein
expression were associated with shorter BCSS compared with SPAG5 copy number variants loss-
neutral (METABRIC: HR, 1.55 [95% CI, 1.18-2.04]; P < .001; Swegene: HR, 2.27 [95% CI, 1.14-4.45];
P = .03), no SPAG5 expression in mRNA (METABRIC: HR, 1.65 [95% CI, 1.31-2.09]; P < .001; Swegene:
HR, 3.20 [95% CI, 2.25-5.70]; P < .001), and no SPAG5 expression in protein (NUH-ESBC: HR, 1.90
[95% CI, 1.51-2.47]; P < .001; QBCFU: HR, 2.57 [95% CI, 1.49-4.42]; P = .02) (eFigure 1 in the
Supplement).
SPAG5 transcript expression was associated with shorter BCSS compared with no SPAG5
transcript expression in disease without lymph node involvement (METABRIC: HR, 2.07 [95% CI,
1.39-3.08]; P < .001) or with lymph node involvement (METABRIC: HR, 1.40 [95% CI, 1.05-1.87];
P = .02). Similarly, SPAG5 protein expression was associated with shorter BCSS compared with no
SPAG5 protein expression in disease without lymph node involvement (NUH-ESBC: HR, 2.21 [95%CI,
1.52-3.21]; P < .001) or with lymph node involvement (NUH-ESBC: HR, 1.70 [95% CI, 1.25-2.39];
P < .001) (eFigure 2 in the Supplement).
In theMC-GEDs cohort, high SPAG5 amplification signature was significantly associated with
shorter OS compared with low SPAG5 amplification signature in all patients (HR, 1.96 [95% CI,
1.72-2.22]), as well as in the subclass of patients without HER2 expression (HR, 2.17 [95% CI,
1.81-2.63]) and with HER2 expression (HR, 1.52 [95% CI, 1.27-1.85]) (eFigure 3 in the Supplement).
Multivariable Cox regressionmodels for 10-year BCSS confirmed that SPAG5 transcript and
SPAG5 protein expressions were associated with higher risk of death after controlling for other
validated prognostic factors (METABRIC: HR, 1.96 [95% CI, 1.72-2.22]; adjusted P < .001; NUH-ESBC:
HR, 1.68 [95%CI, 1.18-2.39]; adjusted P < .001; QBCFU: HR, 1.92 [95%CI, 1.11-3.35]; adjusted P = .02)
(eTable 16 and eTable 17 in the Supplement).
After 2 weeks of preoperative endocrine therapy with aromatase inhibitors, mean (SD) SPAG5
transcript expression was found to be significantly downregulated compared with pretreatment
levels in 68 of 92 patients (74%) (0.23 [0.18] vs 0.34 [0.24]; Z = −5.24; P < .001). There was no
statistically significant further reduction in the level of SPAG5 trascript expression after 3 months
compared with 2 weeks. In 73 of 92 patients with responding tumors (76%) in the NET cohort, a
significant downregulation of mean (SD) SPAG5 transcript expression in 68 of 73 patients (93%)
occurred by 2 weeks compared with pretreatment levels (0.21 [0.16] vs 0.36 [0.24]; P < .001).
However, in patients with nonresponding tumors, there was no significant change in SPAG5
transcript levels by either 2 weeks or 3 months compared with pretreatment levels. By 3months of
treatment, median (IQR) SPAG5 transcript was highly expressed in patients with nonresponding
tumors compared with patients with responding tumors (0.36 [0.14-0.48] vs 0.18 [0.11-0.25]; Mann-
Whitney P = .01) (eFigure 4 in the Supplement).
After receiving NACT, patients with SPAG5 transcript and SPAG5 protein expressions had higher
pathological CR compared with patients without SPAG5 transcript and SPAG5 protein expressions
(MC-NACT cohort: 86 of 430 patients [20%] vs 58 of 627 patients [9%]; odds ratio [OR], 2.45 [95%
CI, 1.71-3.51]; P < .001; NUH-LABC: 28 of 118 patients [24%] vs 9 of 221 patients [4%]; OR, 7.32 [95%
CI, 3.33-16.22]; P < .001). Expression of SPAG5 transcript or SPAG5 protein were associated with a
higher pathological CR rates compared with no SPAG5 transcript or SPAG5 protein expressions in
patients who received either NACT alone (transcript: 26 of 103 patients [25%] vs 19 of 162 patients
[12%]; P < .001; protein: 6 of 38 patients [16%] vs 0 of 62 patients [0%]; P < .001), or NACT with
taxane (transcript: 50 of 294 patients [17%] vs 36 of 447 patients [8%]; P < .001; protein: 16 of 43
patients [37%] vs 5 of 128 patients [4%]; P < .001). In patients with HER2 expression who received
NACT with taxane and trastuzumab, patients with SPAG5 protein expression had statistically
significantly higher pathological CR compared with patients without SPAG5 protein expression (6 of
12 patients [50%] vs 2 of 22 patients [9%]; P = .01) (Figure 2).
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Notably, patients without HER2 expression but with SPAG5 transcript expression had 2-fold
higher pathological CR after receiving NACT alone compared with those who received NACTwith
taxane (21 of 74 patients [28%] vs 38 of 245 patients [16%]; OR, 2.16 [95% CI, 1.17-3.98]; P = .01].
Strikingly, no patients without HER2, SPAG5 transcript, or SPAG5 protein expressions who received
NACT alone achieved pathological CR. However, patients with HER2 and SPAG5 transcript
expressionswho receivedNACTwith taxane had similar pathological CR comparedwith patients who
received trastuzumab in addition to NACTwith taxane (12 of 48 patients [25%] vs 10 of 33 patients
[30%]; P = .60) (Figure 2). Multivariable logistic regression models revealed that expressions of
SPAG5 in transcript (MC-NACT cohort: OR, 1.92 [95% CI, 1.01-3.64]; P = .05; MDACC cohort: OR, 0.03
[95% CI, 0-0.50]; P = .01) and SPAG5 protein (NUH-LABC cohort: OR, 23.03 [95% CI, 7.26-73.02];
P = 0.01) were independently associated with pathological CR (Table 1).
Of 57 patients with SPAG5 protein expression before NACT, 31 patients (54%) had been
converted to no SPAG5 protein expression in their residual post-NACT surgical specimens after
receiving NACT. Among 185 patients without SPAG5 protein expression before NACT, 13 patients
(7%) had SPAG5 protein expression in the residual tissue (McNemar P = .01).
In patients without HER2 overexpression who received NACT followed by 5-year adjuvant
endocrine therapy, we observed a similar 5-year DRFS among patients with and without SPAG5
transcript expression (MDACC: HR, 1.18 [95% CI, 0.74-1.88]; P = .50) and among patients with and
without SPAG5 protein expression (NUH-LABC: HR, 0.83 [95% CI, 0.48-1.42]; P = .49) (eFigure 5 in
Figure2.TheAssociationofPathological CompleteResponseWithSperm-AssociatedAntigen5 (SPAG5) Expression
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the Supplement). However, in patients with residual disease after NACT, SPAG5 protein expression
was associated with shorter 5-year DRFS compared with no SPAG5 protein expression (NUH-LABC:
HR, 3.73 [95% CI, 2.29-9 6.10]; P < .001) (Figure 3A).
Among patients without lymph node involvement, SPAG5 protein expression, compared with
no SPAG5 protein expression, was associated with shorter DRFS in patients who did not receive
systemic adjuvant therapy (HR, 1.82 [95% CI, 1.27-1.59]; P = .001) or received adjuvant endocrine
therapy alone (HR, 2.52 [95% CI, 1.53-4.16]; P < .001) (eFigure 5 in the Supplement). Among patients
who received adjuvant endocrine therapy and chemotherapy, there was no significant difference in
DRFS between patients with or without SPAG5 protein expression (HR, 0.33 [95% CI, 0.04-2.67];
P = .30). Among patients without lymph node involvement, those with SPAG5 transcript expression
who received adjuvant endocrine therapy with chemotherapy had longer 5 year DRFS (45 of 51
patients [89%]) compared with those who received adjuvant endocrine therapy alone (97 of 145
patients [67%]) or did not receive adjuvant therapy (125 of 205 patients [61%]). There were no
significant differences in DRFS among patients without SPAG5 transcript expression (eFigure 6 in the
Supplement).
In patients with lymph node involvement, SPAG5 protein expression was associated with
shorter DRFS in those who received adjuvant endocrine therapy alone compared with those without
SPAG5 protein expression (NUH-ESBC: HR, 2.24 [95% CI, 1.29-3.90]; P = .004) (Figure 3B). Among
patients with lymph node involvement who received adjuvant endocrine therapy with
chemotherapy, there was no significant difference in DRFS between patients with or without SPAG5
protein expression (NUH-ESBC: HR, 1.00 [95%CI, 0.61-1.64]; P > .99) (eFigure 6 in the Supplement).
Patients with SPAG5 transcript expression and lymph node involvement who received adjuvant
Table 1. Multivariable Logistic RegressionModel Analysis for Pathological Complete Response
After Neoadjuvant Chemotherapy Among PatientsWith Estrogen Receptor–Positive Breast Cancer
Variables OR (95% CI) P value
Multivariable logistic regression models analysis for MC-NACT cohort
High SPAG5 mRNA expressiona 1.92 (1.01-3.64) .047
HER2 overexpressiona 3.03 (1.34-6.88) .008
Histological grade 3b 2.33 (1.25-4.34) .008
PAM-50 molecular subclasses
PAM50-LumA 1 [Reference]
.01
PAM50-LumB 0.24 (0.07-0.82)
PAM50-HER2 0.97 (0.23-4.03)
PAM50-Basal-like 0.72 (0.15-3.40)
PAM50-Normal-like 0.32 (0.10-1.09)
Received trastuzumab neoadjuvant chemotherapyc 0.66 (0.20-2.16) .49
Multivariable logistic regression models analysis for MDACC cohort
SPAG5 transcript d 0.03 (0.002-0.5) .01
Ki67 expressiond 1.33 (0.7-2.52) .38
Histological grade 3b 2.7 (1.25-5.82) .01
SPAG5*Ki67*grade 1.62 (1.06-2.46) .03
Chemosensitivity prediction 4.96 (2.79-8.83) <.001
Pathological CR prediction signaturea 2.27 (1.2-4.27) .01
LumBe 0.2 (0.07-0.58) .003
Multivariable logistic regression models analysis for NUH-LABC neoadjuvant cohort
High SPAG5 protein expressiona 23.03 (7.26-73.02) <.001
Histological gradeb 2.37 (1.15-4.89) .02
Patient agef 0.99 (0.96-1.01) .26
HER2 expressiond 5.83 (1.97-17.22) .001
Progesterone receptord 0.23 (0.88-0.69) .009
Received taxane neoadjuvant treatmentc 1.52 (0.4-5.85) .54
Abbreviations: CR, complete response; HER2, human
epidermal growth factor receptor 2; MC-NACT,
multicenter neoadjuvant anthracycline combination
based chemotherapy; MDACC, MD Anderson Cancer
Center taxane/anthracycline-based neo-adjuvant
cohort; NUH-LABC, NottinghamUniversity Hospital
locally advanced breast cancer; OR, odds ratio; SPAG5,
sperm-associated antigen 5.
a Using low as the reference.
b Using grade 1 or 2 as the reference.
c Using not receiving the treatment as the reference.
d Using no expression as the reference.
e Using PAM50-LumA as the reference.
f Continuous variable, OR is given per 1-year increase.
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endocrine therapy with chemotherapy had longer 5-year DRFS (144 patients [76%]) compared with
those who received adjuvant endocrine therapy alone (104 patients [54%]), whereas there was no
significant difference among patients without SPAG5 transcript expression and with lymph node
involvement (Figure 3C and D).
Amultivariate Cox regressionmodel for 5-year DRFS confirmed that SPAG5 transcript (HR. 2.59
[95% CI, 1.69-3.97]; P < .001) or SPAG5 protein (HR, 1.68 [95% CI, 1.18-2.93]; P = .004) were
associated with poor prognosis after controlling for adjuvant endocrine therapy and other validated
prognostic factors. The interaction-term of SPAG5 transcript expression with chemotherapy was
statistically significant (HR, 0.33 [95% CI, 0.17-0.67]; P = .002) (Table 2).
Discussion
SPAG5 is a microtubule-associated protein required for mitotic spindle formation and chromosome
segregation, and its depletion causes multipolar spindle formation, aneuploidy, and cell death.17 In
this cohort study, we have validated SPAG5 as a biomarker associated with endocrine therapy and
chemotherapy in estrogen receptor–positive breast cancers, in agreement with previous studies in
breast,8,18 lung,19 and cervical cancers.17 Our data also suggested that SPAG5 could be an important
genetic driver in estrogen receptor–positive breast cancer,8,9 as SPAG5 dysregulation could
Figure 3. Distant Relapse–Free Survival AssociatedWith Sperm-Associated Antigen 5 (SPAG5) Expression in Patients with Estrogen Receptor–Positive Breast Cancer
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contribute to high chromosomal instability and aneuploidy, which are hallmarks of malignant cells
and confer susceptibility to chemotherapy. Unlike most currently used clinicopathological and
multigene tests, SPAG5 has also potential as a predictive andmonitoring tool for endocrine therapy
and chemotherapy response. Moreover, SPAG5 downregulation after neoadjuvant endocrine therapy
and NACT is associated with the clinical outcome of the adjuvant endocrine therapy. SPAG5
expression could be associated with differential sensitivity to anthracycline and taxane. These
findings are in agreement with previous studies that suggested anthracycline works best in tumors
Table 2. Multivariable Cox RegressionModels Analysis of 5-Year Distant Relapse Free Survival Among Patients
With Estrogen Receptor–Positive Breast Cancer
Variables HR (95% CI) P value
MC-AT cohort
Overall model for SPAG5 transcript expression
SPAG5 mRNAa 2.59 (1.69-3.97) <.001
MKI67 mRNAa 0.99 (0.49-1.71) .77
Lymph node statusb 1.81 (1.01-1.29) .001
Tumor size, cm
≤2 1 [Reference]
.03
>2 1.46 (1.04-2.05)
Progesterone receptorc 0.63 (0.43-0.91) .01
Histologic grade
Low 1 [Reference]
.005Intermediate 2.59 (1.34-5.01)
High 3.18 (1.59-6.36)
Size 1.01 (1.007-1.015) <.001
Endocrine and chemotherapies
No systemic therapy 1 [Reference]
.004Endocrine therapy alone 0.57 (0.27-1.18)
Endocrine therapy with chemotherapy 0.29 (0.13-0.66)
Anthracycline chemotherapy*SPAG5 0.33 (0.17-0.67) .002
SPAG5 vs PAM-50 molecular classes
PAM-50 molecular subclasses
PAM50-LumA 1 [Reference]
.09
PAM50-LumB 1.58 (0.91-2.72)
PAM50-HER2 1.41 (0.85-2.34)
PAM50-basal-like 0.86 (0.62-1.18)
PAM50-normal-like 1.18 (0.85-1.64)
SPAG5 mRNA overexpressionc 1.85 (1.26-2.70) .002
NUH-ESBC cohort
Overall model for SPAG5 protein expressionc
SPAG5 protein expression 1.68 (1.18-2.93) .004
Ki67 protein expression 0.71 (0.47-1.06) .09
TOP2A protein expression 0.91 (0.65-1.27) .57
Tumor sized 1.59 (1.23-2.07) <.001
Lymph node status
Negative 1 [Reference]
<.001
Positive 1.72 (1.44-2.05)
Histological grade
Low or intermediate 1 [Reference]
<.001
High 2.63 (2.10-3.30)
HER2 overexpressionc 1.68 (1.22-2.32) .004
Anthracycline chemotherapye 0.68 (0.48-0.94) .02
Endocrine therapye 0.76 (0.56-1.03) .08
Abbreviations: HER2, human epidermal growth factor
receptor 2; HR, hazard ratio; MC-AT, multicenter
adjuvant therapy; SPAG5, sperm-associated antigen 5.
a Using low as the reference.
b Using no involvement as the reference.
c Using no expression as the reference.
d Continuous variable, HR is given per 1-cm increase.
e Using not receiving the treatment as the reference.
JAMANetworkOpen | Oncology Association of SPAG5 With Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer
JAMA Network Open. 2020;3(7):e209486. doi:10.1001/jamanetworkopen.2020.9486 (Reprinted) July 7, 2020 10/14
Downloaded From: https://jamanetwork.com/ University of Sheffield by Graham Pockley on 10/02/2020
with higher proliferation and chromosomal instability,20,21 whereas endocrine therapy and taxane
work best in chromosomally stable low proliferative breast cancer.15,22
Studies from 201323 and 200824 have shown that combining chemotherapy, and PI3K or mTOR
inhibitors with endocrine therapy restores endocrine therapy responsiveness. In this study and our
previous work,8 SPAG5 transcript and SPAG5 protein expressions were associated with factors that
have been reported to be associated with endocrine therapy resistance and could be a target for
novel therapeutic strategies in endocrine therapy resistance (eg, FOXM1 [OMIM602341], mTOR [OMIM
601231], and ESPL1 [OMIM 604143] and their corresponding proteins).25 SPAG5 downregulation has
been reported to alter mTOR activity and eventually influence the apoptosis.17 Experiments in cervical
cancer have demonstrated that SPAG5 exerts a vital moderating effect on taxol treatment by switching
apoptosis off and on via mTOR.17 Moreover, downregulation of SPAG5 has been demonstrated after
treatment with endocrine therapy,15 PI3K inhibitor, mTOR inhibitors, and trastuzumabwhen combined
with taxol.23,24 Therefore, SPAG5 may not only monitor the response to endocrine therapy, but also
could be used to select patients who would benefit from additional therapeutic drugs.
Examination of most breast cancer prognostic tests or assays shows that the proliferation
cassette is common to all.26 However, most of these tests do not predict the therapeutic benefit from
chemotherapy or endocrine therapy. For instance, although the Oncotype DX test (Oncotype IQ) is
informative, the decision regarding systemic therapy remains challenging for clinicians for more than
50%of patients with estrogen receptor–positive early breast cancer.26,27 Moreover, the routine use
of Ki67 in clinical practice has been limited by the lack of its standardization assessment28 and by its
lack of success in treatment decision-making in several clinical trials.29,30
Limitations
This study has some limitations. Themain limitation of our study is that it was a retrospective
observational study. Although it accumulated data from a large number of unselected patients, the
patients were neither standardized nor uniformly treated. Therefore, validation of our results in a
prospective clinical trial is recommended. Moreover, there is no direct comparison of SPAG5 with
Oncotype DX.
Conclusions
This cohort study found that SPAG5 transcript and SPAG5 protein expressions were associated with
therapeutic response. This gene and its associated protein could potentially be used to match and
monitor effective drugs with individual patients.
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